Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cholangitis is a marker of gastrointestinal cancer

A study in the latest issue of Gut investigates cholangitis and subsequent gastrointestinal cancer risk.

News image

While patients with gastrointestinal cancer are at increased risk of cholangitis, it is less clear whether cholangitis is also a marker for occult gastrointestinal cancer.

If an undiagnosed cancer obstructs the bile duct system and causes cholangitis, the short-term risk of cancer will appear increased.

However, an increased long-term risk of cancer may originate from chronic inflammatory processes.

Dr Kirstine Kobberøe Søgaard and colleagues from Denmark assessed the risk of a gastrointestinal cancer diagnosis subsequent to a cholangitis diagnosis during a 17-year period in Denmark.

The researchers conducted a nationwide population-based cohort study by linking Danish medical registries during 1994–2010.

The team quantified the excess risk of cancer in cholangitis patients using relative and absolute risk calculations.

The team found that 4333 patients with cholangitis were followed for 17,222 person-years.

During the follow-up period, 477 gastrointestinal cancers occurred versus 59 expected, corresponding to a SIR of 8.12.

The research team found that risk was increased mainly for cancer in the small intestine, liver, gallbladder and biliary tract and pancreas.

The team noted that during the first 6 months of follow-up, 314 patients were diagnosed with gastrointestinal cancer, corresponding to a SIR of 49.8, and an EAR of 175.

Dr Søgaard's team commented, "Cholangitis is a marker of occult gastrointestinal cancer."

Gut 2014; 63: 356-361
21 January 2014

Go to top of page Email this page Email this page to a colleague

 28 April 2015

Advanced search
 28 April 2015 
Risk factors of hepatocellular carcinoma
 28 April 2015 
Alcohol drinking and risk of liver cirrhosis
 28 April 2015 
Clinical outcomes after esophagectomy
 24 April 2015 
GastroHep.com Easter break
 23 April 2015 
Gut microbiota modulation for alcoholic liver disease
 23 April 2015 
Moderate sodium restriction diet in cirrhosis
 23 April 2015 
Gastroesophageal junction disruption and obesity
 22 April 2015 
Hepatitis and mortality in hospitalized patients
 22 April 2015 
Magnetic sphincter augmentation for GERD
 22 April 2015 
Drug, herbal and dietary supplement hepatotoxicity
 21 April 2015 
Tracking colonoscopy surveillance intervals
 21 April 2015 
PPI increases risk of cryptogenic liver abscess
 21 April 2015 
Risk factors of postpartum bowel changes
 20 April 2015 
IBS after traveller's diarhea
 20 April 2015 
Economic impact of C. diff infection
 20 April 2015 
Adherence to Hep C treatments
 17 April 2015 
Synchronous colorectal advanced neoplasia
 17 April 2015 
PNPLA3 polymorphisms and NAFLD risk
 17 April 2015 
MELD score and colorectal resection
 16 April 2015 
Bleeding risk in colonic diverticulosis
 16 April 2015 
Minority use of high-volume hospitals for colorectal cancer
 16 April 2015 
Sleep and IBD
 15 April 2015 
Treatment of hepatocellular carcinoma
 15 April 2015 
Score predicts malignant bile duct obstruction
 15 April 2015 
Increased risk of Barrett esophagus
 14 April 2015 
Improving colorectal cancer screening uptake
 14 April 2015 
Colorectal cancer presenting under the age of 50
 14 April 2015 
Functional constipation vs constipation predominant IBS
 13 April 2015 
Fecal transplant for C. difficile
 13 April 2015 
Immune based treatments for HCC
 13 April 2015 
CRP and acute diverticulitis
 10 April 2015 
Hypnotherapy for IBS
 10 April 2015 
Adjuvant therapy after rectal cancer
 10 April 2015 
Viral outcomes in HCV infection
 09 April 2015 
Male IBD patients wishing to conceive
 09 April 2015 
Screening programs based on the fecal immunochemical test
 09 April 2015 
Management of esophageal food impaction
 08 April 2015 
Nonceliac gluten sensitivity
 08 April 2015 
Ambulatory hemorrhoidal surgery
 08 April 2015 
Iron fortification and gut inflammation
 07 April 2015 
Treatment of Hep C virus
 07 April 2015 
Interventions for eosinophilic esophagitis
 07 April 2015 
Endoscopic managements of GI bleeds
 06 April 2015 
Risk stratifying Barrett's esophagus
 06 April 2015 
Cost-effectiveness of HCV
 06 April 2015 
Treatment for rectal cancer
 03 April 2015 
Predicting advanced cancer in Barrett's
 03 April 2015 
Vitamin D deficiency and Hep B outcomes
 03 April 2015 
Hepatocellular carcinoma surveillance in cirrhosis
 02 April 2015 
Physical activity and NAFLD
 02 April 2015 
Genetic risk for Crohn's disease
 02 April 2015 
EUS for detection of pancreatic neuroendocrine tumors
 01 April 2015 
Obeticholic acid in primary biliary cirrhosis
 01 April 2015 
Analysis of liver fibrosis
 01 April 2015 
Mortality rates for upper GI bleeds
 31 March 2015 
HCV-HIV co-infection combination therapy
 31 March 2015 
Placement of nasoenteral feeding tubes
 31 March 2015 
Hepatic fat and gallbladder polyps
 30 March 2015 
Minimally invasive approach in colorectal procedures
 30 March 2015 
Prevalence of IBD in USA residents of Indian ancestry

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us